Divalproex Sodium Market Dynamics
Increasing prevalence of bipolardisorders around the globe is propelling the DivalproexSodium Market growth. For instance, according to study published in JAMAPsychiatry Journal 2012, in a combined sample of 61,392 adults from 11countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and0.4% for bipolar disorder-II and subthreshold bipolar disorder was 1.4%,yielding a total prevalence estimates bipolar disorder spectrum of 2.4%globally.
Moreover, rising patient poolaround the world affected with epilepsy and migraine headaches is also expectedto boost demand for divalproex sodium market significantly. For instance,according to the World Health Organization 2018 key facts, around 50 millionpeople were globally affected with epilepsy, making it one of the most commonneurological disease, and around 80% of the people with epilepsy live in low-and middle-income countries.
According to The Migraine TrustFacts and Figures estimates, the global prevalence of migraine was 14.7% foryear 2013, that’s around 1 in 7 people. Furthermore, increasing awarenessregarding diseases and various government initiatives to prevent head migraineis expected to propel growth of divalproex sodium market size.
However, black boxed warninggiven by FDA due to the hepatotoxicity, pancreatitis, and high fetal riskassociated with the use of divalproex sodium tablet and other known adversereactions such as birth defects, neurobehavioral adverse effects, and suicidalbehavior are expected to restrain the divalproex sodium market growth.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1913
Divalproex sodium is a Food andDrug Administrator (FDA) approved anti-epileptic drug used to treat migraineheadaches, manic episodes of bipolar disorders, and certain types of seizures.Divalproex sodium is known for its anticonvulsant properties for the treatmentof epilepsy.
Divalproex sodium comes underthree dosage forms: capsule, tablet, and syrup. Divalproex sodium oral tabletis available in brand-names, Depakote ER and Depakote. Divalproex sodium isalso used in various combinational therapies.
The recommended initial dosage ofDepakote for the treatment of bipolar disorders is 750 mg daily, whereas forcomplex partial seizures, initial dosage starts with 10 to 15 mg/kg/day. Also,recommended starting dose for migraine headache is 250 mg twice daily toachieve therapeutic response.
Divalproex Sodium Market –Regional Insights
Based on the region, the globaldivalproex sodium market is segmented into North America, Europe, Latin America,Asia Pacific, Middle East, and Africa. North America, specifically the U.S.divalproex sodium market, holds a major global position among the geographies.Owing to increased government initiatives and rising research and developmentfor the introduction of new product are expected to aid in growth of thedivalproex sodium market in the region.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/divalproex-sodium-market-1913
For instance, In 2011 TheNational Quality Strategy (NQS) was launched as the national strategy forquality improvement in health care, This was led by Agency for HealthcareResearch and Quality on behalf of the U.S. Department of Health and HumanServices (HHS). However, introduction of generic products by market giants inthe region is expected to hamper the market growth in the region. For instance,in 2008, Mylan launched generic of Abbott's Depakote ER in the U.S.
Asia Pacific is expected to showsignificant growth followed by Europe, owing to increased prevalence ofepilepsy and head migraine among the population in the region. For instance,according to study published in the Journal of Global Health 2017, showed thatlifetime epilepsy prevalence was 1.99% in 1990 and 7.15% in 2015 among theChinese population.
Divalproex Sodium Market –Competitive Landscape
Major players operating in theglobal divalproex sodium market includes Zydus Pharmaceuticals, Inc., AbbVieInc., Mylan N.V., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., LupinLimited, Orchid Chemicals & Pharmaceuticals Limited, Sun PharmaceuticalIndustries Ltd., Teva Pharmaceutical Industries Ltd., and Abbott Laboratories.
Market players are engaged inadopting marketing strategies such as mergers, collaborations, induction of newproducts to their portfolio, and acquisition, in order to obtain dominantposition in the market. For instance, in 2017, Zydus Cadila acquired SentynlTherapeutics, a U.S.-based pharma company specialized in marketing of productsin the pain management segment.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1913
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
